Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer

Table 2 Treatment characteristics of intraperitoneal chemotherapy n (%)

Treatment characteristics	Total (n = 38)	Adjuvant group (Group 1, n = 25)	Neoadjuvant group (Group 2, n = 13)
Median	3	3	3
Range	(1-6)	(1-6)	(1-4)
Completion of IP cycles
1	5 (13.2)	4 (16)	1 (7.7)
2	3 (7.9)	1 (4)	2 (15.3)
3	16 (42.1)	8 (32)	8 (61.5)
4	9 (23.7)	8 (32)	1 (7.7)
5	1 (2.6)	1 (4)	0 (0)
6	4 (10.5)	3 (12)	1 (7.7)
IP cisplatin
Starting dose 75 mg/m2	35 (92.1)	24 (96)	11 (84.6)
Dose reduction to 60 mg/m2	11 (28.9)	6 (24)	5 (38.5)
IP paclitaxel
Dose reduction	2 (5.3)	2 (8)	0/13 (0)
Dose omission	20 (52.6)	11 (44)	9 (69.2)
Changed to IV abraxane	3 (7.9)	1 (4)	2 (15.4)
Treatment delay
Delay in starting a new cycle	8 (21.1)	5 (20)	3 (23.1)
Delay in day 8 treatment	8 (21.1)	5 (20)	3 (23.1)
Prophylactic hydration planned	10 (26.3)	7 (18.4)	3 (21.1)

IP: Intraperitoneal.